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Abstract
Background: We hypothesized that among septic ICU patients with Acinetobacter spp. bacteremia (Ac-BSI),
carbapenem-resistant Acinetobacter spp. (CRAc) increase risk for inappropriate initial antibiotic therapy (non-IAAT),
and non-IAAT is a predictor of hospital death.
Methods: We conducted a retrospective cohort study of adult septic ICU patients with Ac-BSI. Non-IAAT was defined
as exposure to initially prescribed antibiotics not active against the pathogen based on in vitro susceptibility testing,
and having no exposure to appropriate antimicrobial treatment within 24 hours of drawing positive culture. We
compared patients who died to those who survived, and derived regression models to identify predictors of hospital
mortality and of non-IAAT.
Results: Out of 131 patients with Ac-BSI, 65 (49.6%) died (non-survivors, NS). NS were older (63 [51, 76] vs. 56 [45, 66]
years, p = 0.014), and sicker than survivors (S): APACHE II (24 [19, 31] vs. 18 [13, 22], p < 0.001) and Charlson (5 [2, 8] vs. 3
[1, 6], p = 0.009) scores. NS were also more likely than S to require pressors (75.4% vs. 42.4%, p < 0.001) and mechanical
ventilation (75.4% vs. 53.0%, p = 0.008). Both CRAc (69.2% vs. 47.0%, p = 0.010) and non-IAAT (83.1% vs. 59.1%, p = 0.002)
were more frequent among NS than S. In multivariate analyses, non-IAAT emerged as an independent predictor of
hospital death (risk ratio [RR] 1.42, 95% confidence interval [CI] 1.10-1.58), while CRAc was the single strongest predictor
of non-IAAT (RR 2.66, 95% CI 2.43-2.72).
Conclusions: Among septic ICU patients with Ac-BSI, non-IAAT predicts mortality. Carbapenem resistance appears to
mediate the relationship between non-IAAT and mortality.
Keywords: Aevere sepsis, Acinetobacter spp, Carbapenem resistance, Inappropriate initial antibiotic therapy, Mortality,
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Background
In its 2013 report titled “Antibiotic Resistance Threats
in the United States, 2013” , the US Centers for Disease
Control and Prevention rated carbapenem resistance as
an urgent (among Enterobacteriaceae) or serious (among
Acinetobacter spp.) threat [1]. Since anti-pseudomonal
carbapenems often represent a last-resort option, emerging
resistance to this class indeed reflects a grave concern. The
growing prevalence of carbapenem-resistant pathogens
makes it difficult for the clinician to choose reliably
what will qualify as initially appropriate antibiotic ther-
apy (IAAT).
Understandably, of greatest concern is carbapenem
resistance among Enterobacteriaceae and Pseudomonas
aeruginosa, as they typically comprise the dominant
organisms encoding carbapenemases [2-5]. Acinetobacter
spp., on the other hand, is a less frequently encountered
pathogen. However, the proportion of carbapenem resist-
ance among Acinetobacter spp. isolates is 2–5 times that
seen in Pseudomonas aeruginosa and Klebsiella spp., and
over an order of magnitude that among E. coli [3].
In the setting of many serious infections, one of the crit-
ical determinants of the outcome is early empiric coverage
for the culprit organism [6-14]. Failing to administer in a
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timely manner an agent that is in vitro active against the
offending pathogen(s) leads to increased mortality and
morbidity. Acknowledgement of this observation has led
to the practice of de-escalation where one often starts
with an initially broad anti-infective (or a combination of
agents) and later narrows the spectrum of coverage when
culture results become available [15]. Unfortunately, for
Acinetobacter spp. it is unclear if and how one can suc-
cessfully execute this strategy, particularly in light of the
fact that most isolates are resistant to last-resort treat-
ment. Similarly, as a matter of health policy and antibiotic
stewardship, it is necessary to appreciate the contribution
of carbapenem resistance to the poor outcomes in infec-
tions with Acinetobacter spp. Gaining insight into the rela-
tionship between resistance and outcomes specifically as it
relates to this pathogen may help clarify the urgency of
the need for novel agents with which to treat it.
We hypothesized that in the setting of severe sepsis or
septic shock due to Acinetobacter spp., failure to receive
IAAT increased the risk of death, and that, as a corol-
lary, carbapenem resistance is a strong determinant of
exposure to non-IAAT.
Methods
Study design and ethical standards
We conducted a single-center retrospective cohort study
from January 2002 to December 2012. Barnes-Jewish
Hospital is a 1,200-bed urban academic medical center
located in St. Louis, MO. The study was approved by the
Washington University School of Medicine Human Stud-
ies Committee and informed consent was waived.
Study cohort
All consecutive adult ICU patients between January 2002
and December 2012 were enrolled if 1). They had a posi-
tive blood culture for Acinetobacter spp., and 2). There
was an International Classification of Diseases, version 9,
clinical modification (ICD-9-CM) code for an acute organ
dysfunction [16]. Only the first episode of sepsis was
included.
Definitions
To be included in the analysis patients had to meet
criteria for severe sepsis based on discharge ICD-9-CM
codes for acute organ dysfunction [16]. Septic shock
was present if vasopressors (norepinephrine, dopamine,
epinephrine, phenylephrine or vasopressin) were initi-
ated within 24 hours of the blood culture collection date
and time. Antimicrobial treatment was deemed IAAT if
the initially prescribed antibiotic regimen was active
against the identified pathogen based on in vitro suscep-
tibility testing and administered within 24 hours follow-
ing blood culture collection; all other regimens were
classified as non-IAAT. Because the role of combination
therapy in treating Acinetobacter spp. is not well defined,
combination therapy was not a criterion for defining
IAAT. We also required that antibiotics be prescribed
for ≥24 hours. Prior antibiotic exposure occurred within
the preceding 90 days, as did prior hospitalization, while
prior bacteremia was defined within 30 days of the current
episode. The bacteremia was deemed to be a healthcare-
associated complication (HAC) if one of the following risk
factors was identified: 1). Need for dialysis; 2). Immune
suppression; 3). Prior hospitalization; 4). Prior antibiotics;
5). Current infection deemed hospital-acquired blood
stream infection (HABSI; onset of infection ≥2 days
after admission). Carbapenem-resistant Acinetobacter spp.
(CRAc) was present if it was the organism that grew out
in at least one blood culture specimen.
Antimicrobial susceptibility testing
The microbiology laboratory performed antimicrobial sus-
ceptibility of the isolates using the disk diffusion method
according to guidelines and breakpoints established by the
Clinical Laboratory and Standards Institute (CLSI) appro-
priate to the year the organism was isolated.
Data elements
Patient baseline characteristics and process of care vari-
ables were collected from the automated hospital medical
record, microbiology database, and pharmacy database
of Barnes-Jewish Hospital. Electronic inpatient and out-
patient medical records available for all patients in the BJC
Healthcare system were reviewed to determine prior anti-
biotic exposure. The baseline characteristics collected in-
cluded: age, gender, race, past history of congestive heart
failure, chronic obstructive pulmonary disease, diabetes
mellitus, chronic liver disease, underlying malignancy, and
end-stage renal disease requiring dialysis. The Acute
Physiology and Chronic Health Evaluation (APACHE) II
and Charlson comorbidity scores were calculated based
on clinical data present during the twenty-four hours after
the positive blood cultures were obtained [17]. This was
done to accommodate patients with community-acquired
and healthcare-associated community-onset infections
who only had clinical data available after blood cultures
were drawn. The primary outcome variable was hospital
mortality. Because we were interested in understanding
the contribution of CRAc to the risk of receiving non-
IAAT, we examined it as a secondary endpoint in a logistic
regression.
Statistical analyses
Continuous variables were reported as means with standard
deviations when distributed normally, or medians with 25th
and 75th percentiles when skewed. Differences between
mean values were tested via Student’s t-test, while those
between medians were examined using the Mann–Whitney
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U test. Categorical data were summarized as proportions,
and the Chi-square test or Fisher’s exact test for small sam-
ples was used to examine differences between groups. We
developed several multiple logistic regression models to
identify clinical risk factors associated with hospital mortal-
ity. In the mortality models, all risk factors that were signifi-
cant at ≤0.20 in the univariate analyses, as well as all
biologically plausible factors even if they did not reach this
level of significance, were included in the corresponding
multivariable analyses. All variables entered into the models
were examined to assess for co-linearity, and interaction
terms were tested. The most parsimonious models were de-
rived using the backward manual elimination method, and
the best-fitting model was chosen based on the c-statistic.
The model’s calibration was assessed with the Hosmer-
Lemeshow goodness-of-fit test. To exclude the influence
of time-dependent covariates on hospital mortality, we
confirmed the risk factors in a Cox proportional hazards
model. Similarly, the most parsimonious model for the pre-
dictors of non-IAAT was computed and its fit was tested
with the c-statistic and the Hosmer-Lemeshow goodness-
of-fit test.
Because both outcomes of interest in each of the
models (mortality and non-IAAT) occurred with high
frequency (overall mortality 49.6%, overall non-IAAT
71.0%), the adjusted odds ratios would overestimate the
magnitude of the actual risk associated with each of the
independent variables examined. For this reason we
corrected the risk estimate according to the method of
Zhang [18], and report the corrected risk ratios.
All tests were two-tailed, and a p value <0.05 was
deemed a priori to represent statistical significance. All
calculations were done in Stata/SE, version 9 (StataCorp,
College Station, TX).
Results
One hundred and thirty-one patients with severe sepsis or
septic shock due to Acinetobacter spp. met the inclusion
criteria. Among these 76 (58.0%) were CRAc. (Table 1 lists
additional drug susceptibilities stratified by carbapenem
resistance). Overall hospital mortality was 49.6%. The pa-
tients’ baseline characteristics are listed in Table 2. Those
who died were older and had a higher comorbidity bur-
den, as signified by the Charlson comorbidity score, than
those who survived their hospitalization. A higher pro-
portion of those patients who died prior to discharge had
dialysis (28.1% vs. 15.2%, p = 0.072), prior antibiotics
(75.4% vs. 57.6%, p = 0.031) and HABSI (72.3% vs. 50.0%,
p = 0.009) as risk factors for a HAC than those who were
discharged alive.
During the hospitalization and prior to sepsis onset,
patients who did not survive had a far longer pre-sepsis
median hospital length of stay (LOS) (13 vs. 2 days, p =
0.002) (Table 3). All markers of severity of acute illness
were higher in patients who died compared to those
who survived; this included the APACHE II score, the
presence of septic shock and the need for mechanical
ventilation (Table 3). Urine and infected line were less
likely and lung was more likely as a source of infection
among non-survivors compared to survivors. In contrast
to pre-sepsis LOS, post-sepsis onset median LOS was far
shorter among those who did not than those who did
survive their hospitalization (4.5 vs. 15 days, p < 0.001).
There were substantial differences between the two
groups in terms of the likelihood of CRAc as the sepsis
culprit (69.2% among non-survivors vs. 47.0%% among
survivors, p = 0.010) (Table 3). Additionally, non-survivors
were approximately 50% more likely to receive non-IAAT
than those patients who survived their hospitalization
(83.1% vs. 59.1%, p = 0.002). Notably, among those pa-
tients who harbored CRAc, the risk for being treated in-
appropriately was 96.1%, compared to 36.4% among those
with a susceptible organism, p < 0.001.
Table 4 shows the results of a multiple logistic regres-
sion model derivation to examine the variables associated
with hospital mortality in this population. In this model,
receiving non-IAAT was the strongest predictor of
hospital death, with the corrected risk ratio of 1.42 (95%
confidence interval 1.10 to 1.58, p = 0.015). A Cox propor-
tional hazards model, confirmed non-IAAT (hazard ratio
2.37, 95% confidence interval 1.16 to 4.85, p = 0.019) and
APACHE II score (hazard ratio 1.08, 95% confidence
interval 1.03 to 1.12, p < 0.001; per 1 point) as risk factors
for hospital death. In an additional logistic regression
model to examine factors that contribute to the inappro-
priate choice of therapy, CRAc as the etiology of sepsis
Table 1 Susceptibilities to additional antimicrobials
stratified by carbapenem susceptibility
Drug Carbapenem-S Carbapenem-NS
S R I NR S R I NR
Cefepime 31 17 2 0 1 74 1 0
Ciprofloxacin 27 17 5 1 0 74 1 1
Gentamycin 37 10 2 1 31 34 10 1
Piperacillin-Tazobactam 22 16 9 3 1 71 3 1
Tobramycin 19 1 0 30 28 20 8 20
Trimethoprim-Sulfamethoxazole 34 13 2 1 8 67 0 1
Amikacin 3 1 0 46 27 20 5 24
Ampicillin-Sulbactam 0 0 2 48 4 16 19 37
Aztreonam 1 0 0 46 41 0 0 35
Colistin 4 0 0 46 53 0 0 23
Minocycline 2 2 0 46 20 24 8 24
Tygecycline 0 2 0 48 5 7 17 47
Doxycycline 0 2 0 48 19 19 2 36
S = susceptible, NS = non-susceptible, R = resistant, I = intermediate,
NR = not reported.
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was a strong predictor of inappropriate treatment, with
the corrected risk ratio measuring 2.66 (95% confidence
interval 2.43 to 2.72, p < 0.001). The only other predictor
retained in the model was congestive heart failure, with
the corrected risk ratio 1.89 (95% confidence interval 1.01
to 2.63, p = 0.048) (AUROC 0.884, Hosmer-Lemeshow
p =0.513).
Discussion
In the current cohort of patients with sepsis due to
Acinetobacter spp., the prevalence of carbapenem resist-
ance was high at nearly 60%. More importantly, the risk
for receiving non-IAAT in this setting was extreme.
Specifically, the presence of CRAc as the infectious
pathogen more than doubled the risk of receiving non-
IAAT compared to having a carbapanem-susceptible iso-
late. Additionally, despite the high baseline rate of death
in patients with Acinetobacter spp. sepsis, failure to re-
ceive appropriate therapy further increased the risk of
hospital mortality.
A vast volume of research has emphasized the import-
ance of early appropriate antimicrobial therapy in the
setting of serious infections. Indeed, it has been shown in
sepsis and pneumonia that the penalty for the wrong choice
of empiric treatment is a 2-4-fold increase in the risk of
death [6-8,10-14], and that escalation of treatment in
response to culture results fails to mitigate this increase in
risk [9]. Our findings generally confirm this relationship.
However, the current study adds to these earlier analyses by
focusing specifically on a pathogen that is generally only
sporadically found in US ICUs. The majority of earlier stud-
ies dealing with inappropriate therapy has addressed spe-
cific disease states (e.g., pneumonia), irrespective of the
Table 2 Baseline characteristics
Died % Survived % P value











Gender, male 32 49.23% 32 48.48% 0.932
Comorbidities
CHF 24 36.92% 14 21.21% 0.048
COPD 23 35.38% 17 25.76% 0.232
CLD 10 15.38% 3 4.55% 0.038
DM 26 40.00% 12 18.18% 0.006
CKD 22 33.85% 10 15.15% 0.013
CA 13 20.00% 13 19.70% 0.965
Charlson
Mean [SD] 5.3 [3.6] 3.7 [3.3]
Median (IQR) 5 (2, 8) 3 (1, 6) 0.009
Admission source
Home 31 47.69% 32 48.48% 0.928
Another hospital 15 23.08% 21 31.82% 0.262
NH/ECF 16 24.62% 11 16.67% 0.261
Unknown 3 4.62% 2 3.03% 0.680
HAC RFs
Dialysis 18 28.12% 10 15.15% 0.072
Immune
suppression
19 29.23% 15 22.73% 0.396
Prior hospitalization 47 72.31% 46 69.70% 0.742
Prior antibiotics 49 75.38% 38 57.58% 0.031
HABSIa 47 72.31% 33 50.00% 0.009
SD = standard deviation; IQR = interquartile range; CHF = congestive heart
failure; COPD = chronic obstructive pulmonary disease; CLD = chronic liver
disease; DM = diabetes mellitus; CKD = chronic kidney disease; CA = cancer;
NH = nursing home; ECF = extended care facility; HCA = healthcare-associated;
RF = risk factors.
aHospital-acquired BSI defined as BSI that developed after day 2
of hospitalization.
Table 3 Infection characteristics
Died % Survived % P value
n = 65 49.62% n = 66 50.38%
LOS prior to
bacteremia, days
Mean [SD] 17.1 [23.2] 8.2 [9.9]
Median (IQR) 13 (1, 22) 2 (0, 14) 0.002
APACHE II
Mean [SD] 24.4 [7.9] 18.2 [6.4]
Median (IQR) 24 (19, 31) 18 (13, 22) <0.001
Septic shock 49 75.38% 28 42.42% <0.001
Mechanical
ventilation
49 75.38% 35 53.03% 0.008
Polymicrobial 10 18.52% 15 31.91% 0.120
Infection sourcea
Lung 22 36.67% 19 30.16% 0.575
Urine 8 13.33% 23 36.51% 0.003
Abdomen 12 20.00% 5 7.94% 0.048
Line 5 8.33% 8 12.70% 0.308
Unknown 13 21.67% 8 12.70% 0.425
CRAc 45 69.23% 31 46.97% 0.010




Mean [SD] 13.0 [27.0] 19.9 [18.2]
Median (IQR) 4.5 (2, 16.5) 15 (6, 33) <0.001
LOS = length of stay; SD = standard deviation; IQR = interquartile range;
CRAc = carbapenem-resistant Acinetobacter spp.; IAAT = initially appropriate
antibiotic therapy.
aMultiple sources possible.
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pathogen, or has not attempted to measure impact of
inappropriate therapy in the setting of sepsis and septic
shock as a syndrome. In this vein, few earlier efforts have
dealt specifically with the issue of Acinetobacter spp. as a
cause of bacteremia, and no other to the best of our know-
ledge has examined severe sepsis/septic shock. Indeed, the
data on whether non-IAAT in the setting of Acinetobacter
bacteremia as a contributor to the increase in the risk of
death are conflicting. A small multi-center retrospective
matched cohort study from Korea reported that non-
IAAT was associated with a 6-fold increase in 30-day mor-
tality [19]. Similarly, a single-center study from Turkey
reported a nearly identical risk of 30-day morality to ours
in association with non-IAAT (hazard ratio 2.1, 95% CI
1.2-3.7; P = 0.007) [20]. In contrast, several other studies
failed to detect this relationship, though each suffered
from a small sample size of bacteremia cases and other
methodologic issues [21-24]. A cohort study from Turkey
examining 100 cases of Acinetobacter bacteremia reported
that carbapenem resistance was an independent risk factor
for 14-day mortality [25]. However, while inappropriate
empiric treatment was associated with an increase in mor-
tality in the univariate analysis, it was not reported to be
so in a multivariate analysis. It is unclear whether it was
included in such and fell out or whether it was simply not
examined. In either case, since we have demonstrated
strong collinearity of non-IAAT with carbapanem resist-
ance, including both in a single regression would not be
statistically desirable. Another small cohort study con-
ducted in the US examining the relationship between
carbapenem resistance and mortality in A. baumanii
bacteremia failed to detect an association, although appro-
priateness of treatment was an important determinant
of hospital death [26]. However, such strong collinearity
between non-IAAT and CRAc as we have detected in our
study suggests that they may exist in the same causal path-
way vis-à-vis outcomes. For this reason, it may be more
statistically valid to examine them separately, as we have
done, rather than in the same model.
Importantly, none of the above studies focused on the
syndrome of sepsis. Because of the populations addressed
in and limitations of earlier reports, ours expands upon
past research exploring the mortality burden specifically
related to Acinetobacter spp. severe sepsis and septic
shock. Significantly, we illustrate that although outcomes
are generally poor in persons infected with this organism,
the additional impact of inappropriate therapy is substan-
tial. As such, this suggests that there is an urgent need for
agents that can provide empiric coverage for this patho-
gen. This last point is even more crucial in that the preva-
lence of drug-resistant Acinetobacter spp. is increasing
both in the US and across the globe [27]. Thus, what may
currently be of only a limited burden may in the future be-
come much more of an issue. Conversely, our results
emphasize the importance of public policy tools that foster
drug development, such as the GAIN act, as well as the
Food and Drug Administration’s attention to streamlining
the development of antibacterial therapies in the setting of
unmet medical needs [28].
Our results further suggest that carbapenem resistance
is an important risk factor for receiving inappropriate em-
piric coverage. In other words, the key issue may not only
be rapid identification of subjects specifically at risk for
Acinetobacter spp., but may in fact be determining whether
a patient is suffering from a potentially carbapenem-
resistant pathogen. This not only highlights the urgent need
for concerted efforts at preventing individual infections
and curtailing the development and spread of resistant
organisms, but also underscores the needs for novel rapid
diagnostic tools. Moreover, these new diagnostics must pro-
vide clinicians up front with information about a pathogen’s
likely susceptibilities rather than just simply identifying the
organism.
Our study has a number of limitations. As a retrospective
cohort it is prone to several forms of bias, most notably
selection bias. We attempted to mitigate this by enrolling
consecutive patients fitting the pre-determined enrollment
criteria. Although we dealt with confounders by adjusting
for those that were available, it is possible that some
residual confounding remains, particularly confounding by
indication. The fact that this is a single-center study in a
very specific population of patients (those with Acinetobac-
ter spp. sepsis) may diminish the generalizability of our
results to other centers and populations. An additional
potential threat to the generalizability of the findings is the
fact that non-susceptibility to carbapanems was based on
the corresponding year’s CLSI threshold for resistance.
Applying higher MIC cut-offs either for carbapenems
or other agents that have shown at least some in vitro sus-
ceptibilities at higher MICs would have reclassified some
of the non-IAAT patients into the IAAT category [29,30].






Non-IAAT 1.418 1.099-1.583 0.015




*Factors excluded from the model for collinearity: chronic kidney disease,
hemodialysis, chronic obstructive pulmonary disease, diabetes mellitus (collinear
with congestive heart failure); hospital-acquired blood stream infection, LOS prior
to the onset of sepsis (collinear with prior antibiotics); Charlson comorbidity score
(collinear with age)’ mechanical ventilation, vasopressors (collinear with APAHCE
II); carbapenem resistance (collinear with non-IAAT).
Factors included but not retained in the model at the p < 0.05: congestive
heart failure, chronic liver disease, prior antibiotics, age, prior hospitalization,
polymicrobial infection, infection sources urine and abdomen.
IAAT = initially appropriate antibiotic therapy.
AUROC =0.801, Hosmer-Lemeshow p = 0.406.
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This reclassification would have the potential either to
strengthen or to weaken the association between non-
IAAT and mortality. It is important to note that, although
our results strongly suggest that the association of carba-
penem resistance with an increased risk of death is mech-
anistically related to the risk of receiving inappropriate
empiric therapy, we cannot rule out that resistant Acineto-
bacter spp. may exert its lethal effect directly by virtue of
higher virulence, as has been noted with other pathogens
exhibiting higher MICs to certain antimicrobials [31,32].
Because we examined hospital mortality rather than the
more standard 28-day mortality as the primary outcome
for our study, we may have underestimated the magnitude
of this outcome.
Conclusions
In summary, our study sheds light on the mechanism for
the detrimental effect on mortality of exposure to non-
IAAT in the setting of Acinetobacter spp. sepsis. Namely,
it is the pathogen’s resistance to carbapenems, the class of
last resort, that appears to mediate at least in part this
adverse outcome. In this way, this pathogen is an eloquent
illustration of a recent World Health Organization’s state-
ment: “A post-antibiotic era – in which common infec-
tions and minor injuries can kill – far from being an
apocalyptic fantasy, is instead a very real possibility for the
21st Century” [33].
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